Bernard R. Tegtmeier

Bernard R. Tegtmeier

Auto-generated profile, based on publicly available information

Bernard R. Tegtmeier

Department of Quality Risk and Regulatory Management, City of Hope National Medical Center , Duarte, California , USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2022 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Open access
PDF file
JDJana Kubrin Dickter
Jana Kubrin Dickter
JRJustine A. Ross
Justine A. Ross
JZJasmine M. Zain
Jasmine M. Zain
BTBernard R. Tegtmeier
Bernard R. Tegtmeier
BLBrian V. Lee
Brian V. Lee
SDSanjeet Dadwal Dadwal
Sanjeet Dadwal Dadwal
What is known and objective Management of pan-resistant cytomegalovirus infection (CMVi) requires a multifaceted approach, including host defence optimization by reducing immunosuppression, and standard or experimental antiviral therapy. Case description A 36-year-old man with anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma, who underwent allogeneic haematopoietic stem cell transplant (alloHCT) with resultant graft-versus-host disease treated with immunosuppressive therapy, developed pan-resistant CMVi. He was successfully treated with combination therapy of maribavir and letermovir. What is new and conclusion Combination therapy, used for other infections to prevent cross-resistant, may apply for CMVi.

23 July 2024 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
JRJustine Abella Ross
Justine Abella Ross
BLBrian Lee
Brian Lee
HMHuiyan Ma
Huiyan Ma
BTBernard Tegtmeier
Bernard Tegtmeier
DNDeepa Nanayakkara
Deepa Nanayakkara
SDSanjeet Dadwal Dadwal
Sanjeet Dadwal Dadwal
Continuing antifungal prophylaxis (AFPx) to prevent invasive mold infections (IMIs) in recipients of allogeneic hematopoietic cell transplantation (alloHCT) after primary hospital discharge from alloHCT admission varies among transplant centers despite recommendations to continue prophylaxis through day +75. Characteristics driving AFPx prescribing at hospital discharge and outcomes are unknown. In this retrospective analysis, we reviewed patients continuing AFPx vs no AFPx at hospital discharge. We included patients with a hospital stay ≥7 days and ≤40 days. We excluded patients with a history of IMI prior to alloHCT, new IMI during admission, or death prior to discharge. Our primary objective was incidence of probable or proven IMI per the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Our secondary objectives were nonrelapse mortality at day +100, overall survival at day +100, and characteristics driving AFPx discontinuation at hospital discharge. Of the 430 patients identified, 387 met inclusion criteria. At discharge, 56% (217/387) continued AFPx, and 44% (170/387) had no AFPx. At day +100, 3 probable IMI cases occurred in the group with continued AFPx vs 1 probable IMI case in the no-AFPx group (no proven IMI). Univariate analysis showed no difference in cumulative incidence of probable IMI (P = .440), nonrelapse mortality (P = .072), and overall survival (P = .855) between groups. Multivariable logistic regression demonstrated that patients were less likely to continue AFPx if they had a diagnosis other than acute myeloid leukemia, a length of stay ≤30 days, acute graft-vs-host disease grade 0 or 1, and corticosteroid use ≤5 days. There was no difference in probable IMI at day +100 after alloHCT based on continuing vs discontinuing AFPx at hospital discharge after alloHCT admission supporting a risk-adapted prophylaxis approach.